Anglo French Drugs and Industries Unlisted Shares
Anglo-French Drugs & Industries reports standalone net loss of Rs 3.35 crore in the December 2023 quarter
Business Standard
2 min read
Anglo-French Drugs & Industries reports standalone Robust growth: Sales Soar by 36.78% and Net Loss declines significantly for the quarter ended Dec 23
Expert Analysis:
Sales Surge:
Impressive 36.78% Growth to Rs 25.66 crore.
Financial Turnaround:
Net Loss Narrows from Rs 7.06 crore from the previous quarter ended Dec 22 to Rs 3.35 crore for the quarter ended Dec 23.
Operational Efficiency:
OPM Improves from -38.43% to -10.05%.
Strong Performance:
Witnessed a 36.78% Sales Increase.
Financial Stability:
Substantial Reduction in Net Loss.
Operational Efficiency Boost:
Enhanced OPM Reflects Improved Efficiency.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved